Molecular subtypes of muscarinic receptors (m1–m5) are novel targets for cholinergic
replacement therapies in Alzheimer's disease. However, the status of these receptors in …

We have recently reported on the differential alterations of various cholinergic markers in
cortical and subcortical regions in Alzheimer's disease (AD). The main purpose of the …

The relative proportion of super-high, high and low affinity agonist binding sites was
measured in the hippocampus from individuals with dementia of the Alzheimer type …

Autoradiographic labelling of muscarinic (Ml, M2, NMS binding sites) and nicotinic receptors
shows an inhomogeneous distribution over architectonically identified cortical areas of the …

The activity of the acetylcholine synthesizing enzyme choline acetyltransferase
(ChAT)(presynaptic marker) and number of muscarine-like receptor binding sites have been …

Publisher Summary N-[3 H] methylcarbamylcholine (MCC) has recently been used to
characterize nicotinic receptors in the rat central nervous system (CNS). The distribution of [3 …

Muscarinic and nicotinic binding sites were analysed in lymphocytes from patients with
Alzheimer's disease, Multi-infarct dementia, Parkinson's disease and age-matched controls …

In Alzheimer's disease (AD), there is a loss of presynaptic cholinergic markers in the
cerebral cortex, but the nature of cholinergic receptor changes is unclear. In this study,[3 …